The Tapestri Single-cell Multi-omics MRD (scMRD) Assay for AML provides institutions early access to our scMRD technology, which allows for MRD detection with unparalleled resolution, sensitivity, and specificity. At this year’s AMP Annual Meeting & Expo, Aaron Llanso shared how the scMRD technology can be leveraged to improve the identification of residual disease and potential therapeutic strategies, including an overview of scMRD data. He also discussed opportunities for single-cell multi-omics in the clinic for MRD and beyond, and provided an insider look into our scMRD Early Access Program
